ArticleJournal of virology2001
Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells.
Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Injuries from needles contaminated with hepatitis C virus: how high is the risk of seroconversion for medical personnel really?].Der Internist · 2007Pooled it
- HIV-1-specific CD8PNAS nexus · 2025Article
- MORITS: An improved method to predict peptides from heterologous proteins that are recognized by the same T-cell receptor.Scientific reports · 2024Article
- BCG immunization induces CX3CR1Nature immunology · 2024Article
- Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox.Cell host & microbe · 2023Article
- Exposed seronegative: Cellular immune responses to SARS-CoV-2 in the absence of seroconversion.Frontiers in immunology · 2023Review
- CrossDome: an interactive R package to predict cross-reactivity risk using immunopeptidomics databases.Frontiers in immunology · 2023Article
- Chronic HCV infection promotes cytotoxicity in antigen-specific CD8Frontiers in virology (Lausanne, Switzerland) · 2023Article
- Cross-Reactive T Cell Response Exists in Chronic Lymphocytic Choriomeningitis Virus Infection upon Pichinde Virus Challenge.Viruses · 2022Article
- Heterologous Immunity Between SARS-CoV-2 and Pathogenic Bacteria.Frontiers in immunology · 2022Article
- Prospects on Repurposing a Live Attenuated Vaccine for the Control of Unrelated Infections.Frontiers in immunology · 2022Review
- Re-emphasizing mechanism in the community ecology of disease.Functional ecology · 2021Article
- Identification of resident memory CD8Science immunology · 2021Article
- Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection.Hepatology (Baltimore, Md.) · 2021Article
- Expansion of Unique Hepatitis C Virus-Specific Public CD8Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Review
- Virus-Induced T Cell-Mediated Heterologous Immunity and Vaccine Development.Frontiers in immunology · 2020Review
- Harnessing Memory NK Cell to Protect Against COVID-19.Frontiers in pharmacology · 2020Review
- Dynamically characterizing individual clinical change by the steady state of disease-associated pathway.BMC bioinformatics · 2019Article
- Heterologous Immunity: Role in Natural and Vaccine-Induced Resistance to Infections.Frontiers in immunology · 2019Review
49 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
The cellular immune response contributes to viral clearance as well as to liver injury in acute and chronic hepatitis C virus (HCV) infection. An immunodominant determinant frequently recognized by liver-infiltrating and circulating CD8(+) T cells of HCV-infected patients is the HCV(NS3-1073) peptide CVNGVCWTV. Using a sensitive in vitro technique with HCV peptides and multiple cytokines, we were able to expand cytotoxic T cells specific for this determinant not only from the blood of 11 of 20 HCV-infected patients (55%) but also from the blood of 9 of 15 HCV-negative blood donors (60%), while a second HCV NS3 determinant was recognized only by HCV-infected patients and not by seronegative controls. The T-cell response of these healthy blood donors was mediated by memory T cells, which cross-reacted with a novel T-cell determinant of the A/PR/8/34 influenza A virus (IV) that is endogenously processed from the neuraminidase (NA) protein. Both the HCV NS3 and the IV NA peptide displayed a high degree of sequence homology, bound to the HLA-A2 molecule with high affinity, and were recognized by cytotoxic T lymphocytes with similar affinity (10(-8) M). Using the HLA-A2-transgenic mouse model, we then demonstrated directly that HCV-specific T cells could be induced in vivo by IV infection. Splenocytes harvested from IV-infected mice at the peak of the primary response (day 7 effector cells) or following complete recovery (day 21 memory cells) recognized the HCV NS3 peptide, lysed peptide-pulsed target cells, and produced gamma interferon. These results exemplify that host responses to an infectious agent are influenced by cross-reactive memory cells induced by past exposure to heterologous viruses, which could have important consequences for vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.